Table 1 Demographic and clinical characteristics of patients.
Patients (N = 128)* | |
|---|---|
Age at study inclusion, median years (IQR) | 69.2 (59.0–78.9) |
Early breast cancer | |
Time from diagnosis to study inclusion, median years (IQR) | 11.1 (7.6–15.6) |
Histological type, n (%) | |
Ductal carcinoma | 98 (76.6) |
Lobular carcinoma | 20 (15.6) |
Mucinous carcinoma | 3 (2.3) |
Others | 7 (5.5) |
Cancer grade, n (%) | |
N available | 117 |
Grade 1 (Differentiated) | 25 (21.4) |
Grade 2 (Moderately differentiated) | 70 (59.8) |
Grade 3 (Poorly differentiated) | 22 (18.8) |
Hormone receptors, n (%) | |
ER-positive | 88 (68.8) |
PgR-positive | 101 (78.9) |
Ki67 proliferation index, n (%) | |
N available | 121 |
Low (≤ 20%) | 83 (68.6) |
High (> 20%) | 38 (31.4) |
Unknown | 7 |
Type of cancer, n (%) | |
N available | 121 |
Luminal A | 61 (50.4) |
Luminal B | 60 (49.6) |
Unknown | 7 |
Adjuvant treatments, n (%) | |
Chemotherapy | 128 (100.0) |
Hormonal | 128 (100.0) |
Radiotherapy | 128 (100.0) |
Advanced breast cancer** | |
Time from diagnosis to study inclusion, median years (IQR) | 4.0 (2.5–6.0) |
Time from early to advanced disease, median years (IQR) | 6.8 (3.7–10.5) |
Hormone receptors – on biopsy, n (%) | |
N available | 61 |
ER-positive | 38 (62.3) |
PgR-positive | 43 (70.4) |
Unknown | 67 |
Ki67 proliferation index, n (%) | |
N available | 56 |
Low (≤ 20%) | 33 (58.9) |
High (> 20%) | 23 (41.1) |
Unknown | 72 |
Type of cancer, n (%) | |
N available | 85 |
Luminal A | 41 (48.2) |
Luminal B | 44 (51.8) |
Unknown | 43 |
Metastasis location, n (%) | |
Visceral | 62 (48.4) |
Bone | 53 (41.4) |
Local relapse | 13 (10.2) |
Previous treatments in the adjuvant setting, n (%) | |
N available | 127 |
Aromatase inhibitor | 74 (58.3) |
Aromatase inhibitor + tamoxifene | 27 (21.3) |
Tamoxifene | 26 (20.5) |
Unknown | 1 |
Treatment with fulvestrant | |
Time from diagnosis of ABC and start of treatment, median months (IQR) | 0.9 (0.3–1.8) |
ECOG PS at start of treatment, n (%) | |
0 | 66 (51.6) |
1 | 53 (41.4) |
2 | 9 (7.0) |
Duration of the treatment, median months (IQR) | 14.0 (6.9–26.6) |
Endocrine resistance | |
Primary endocrine resistance, n (%) | 24 (18.8), 114 (89.1), and 24 (18.8) *** |
Secondary endocrine resistance, n (%) | 90 (70.3), 114 (89.1), and 104 (81.2) *** |
Hormone-sensitive patients, n (%) | 14 (10.9), 14 (10.9), and 104 (81.2) *** |
